EXOC6B

Across TCGA pan-cancer cohorts, EXOC6B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOC6B data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXOC6B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EXOC6B expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LSCC, and UCEC are the cancer types where EXOC6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.776	0.479	.003	61	view →
LSCC	OS	Median	III,IV	0.373	0.882	<.001	33	view →
UCEC	OS	Median	III,IV	0.494	1.000	.016	28	view →
LUAD	DFS	Median	II,III,IV	0.317	0.747	.002	14	view →
CCRCC	OS	Tertile	III,IV	0.977	0.104	.036	6	view →
GBM	DFS	Quartile	All	0.215	0.524	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOC6B–HNSC (DFS)

Open the HNSC breakdown →